Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

60.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 60.49
Bid (Size) 54.46 (1)
Ask (Size) 60.18 (2)
Prev. Close 60.49
Today's Range 60.49 - 60.49
52wk Range 30.58 - 70.00
Shares Outstanding 109,865,305
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per... 
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
+24.03%
+24.03%
1 Month
+4.28%
+4.28%
3 Month
+25.99%
+25.99%
6 Month
+2.16%
+2.16%
1 Year
+83.08%
+83.08%

More News

Read More
Apellis's Pegcetacoplan Shows Increased Effects In Geographic Atrophy At Two Years
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Via Benzinga
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
Via Benzinga
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Via MarketBeat
Topics Stocks
Exposures US Equities
Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
Via Investor's Business Daily
Investigator Says Apellis' Lead Product Shows 'First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth'
Via Benzinga
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stifel Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Moderna To $165? Plus This Analyst Cuts PT On FedEx
Via Benzinga
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
Via Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Apellis Shares Show Mixed Reaction After Positive 2 Years Data From Late-Stage Retinal Disorder Study
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Why Crypto-Related Companies Traded Higher; Here Are 72 Biggest Movers From Yesterday
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
Via Benzinga
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Climbs Over 500 Points as Upbeat Earnings Roll In
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.